CO Code § 25-1.5-115 (2021)
2021 Colorado Code|Title 25 - Public Health and Environment|Article 1.5 - Powers and Duties of the Department of Public Health and Environment|Part 1 - General Powers and Duties|§ 25-1.5-115. Opiate Antagonist Bulk Purchase Fund - Creation - Definition - Rules - Report

     The opiate antagonist bulk purchase fund, referred to in this section as the “fund”, is hereby created in the state treasury. The fund consists of payments made to the department by participating eligible entities for the purchase of opiate antagonists; gifts, grants, and donations credited to the fund pursuant to subsection (1)(b) of this section; and any money that the general assembly may appropriate or transfer to the fund.    The department may seek, accept, and expend gifts, grants, or donations from private or public sources for the purposes of this section. The department shall transmit all money received through gifts, grants, or donations to the state treasurer, who shall credit the money to the fund.    The state treasurer shall credit all interest and income derived from the deposit and investment of money in the fund to the fund.       Money in the fund is continuously appropriated to the department for bulk purchasing of opiate antagonists. Eligible entities may purchase opiate antagonists from the department. The department may contract with a prescription drug outlet, as defined in section 12-280-103 (43), for the bulk purchasing and distribution of opiate antagonists. The department may prioritize the purchase of opiate antagonists by eligible entities based on the need of the entity and the availability of the opiate antagonists as determined by the department. The department shall provide technical assistance to participating eligible entities to ensure that eligible entities complete all training and registration requirements.    The department shall promulgate rules specifying the amount an eligible entity must pay to purchase opiate antagonists from the department.      No later than October 1, 2020, and every October 1 thereafter, the executive director of the department or the executive director's designee shall report to the house and senate appropriations committees, or their successor committees, on the fund's activity. The report must include:   Revenue received by the fund;    Revenue and expenditure projections for the forthcoming fiscal year and details of all expenditures from the fund;    The eligible entities that purchased opiate antagonists;    The amount of opiate antagonists purchased by each eligible entity; and    The discount procured through bulk purchasing.       Notwithstanding section 24-1-136 (11)(a)(I), the report required in this subsection (4) continues indefinitely.       As used in this section, “eligible entity” means:   A unit of local government, as defined in section 29-3.5-101 (4);    A person making an opiate antagonist available pursuant to section 25-20.5-1001;    The following entities, if the entity has adopted a policy allowing the acquisition, maintenance, and administration of opiate antagonists pursuant to section 22-1-119.1:   A school district board of education of a public school;    The state charter school institute for an institute charter school; or    A governing board of a nonpublic school.       A harm reduction organization, as defined in section 12-30-110 (7)(b);    A law enforcement agency; or    A first responder, as defined in section 12-30-110 (7)(a).         History. Source: L. 2019: Entire section added, (SB 19-227), ch. 273, p. 2580, § 10, effective May 23. L. 2021: (2) and (5)(b) amended and (5)(d), (5)(e), and (5)(f) added, (SB 21-122), ch. 33, p. 137, § 4, effective April 15.